This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karlowsky, J. A.
Right arrow Articles by Sahm, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karlowsky, J. A.
Right arrow Articles by Sahm, D. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2003, p. 1681-1688, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1681-1688.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001

James A. Karlowsky,1* Deborah C. Draghi,1 Mark E. Jones,2 Clyde Thornsberry,3 Ian R. Friedland,4 and Daniel F. Sahm1

Focus Technologies, Herndon, Virginia 20171,1 Focus Technologies, 1217 KP Hilversum, The Netherlands,2 Focus Technologies, Franklin, Tennessee 37064,3 Merck Research Laboratories, West Point, Pennsylvania 194864

Received 22 October 2002/ Returned for modification 21 January 2003/ Accepted 14 February 2003

Pseudomonas aeruginosa and Acinetobacter baumannii are the most prevalent nonfermentative bacterial species isolated from clinical specimens of hospitalized patients. A surveillance study of 65 laboratories in the United States from 1998 to 2001 found >90% of isolates of P. aeruginosa from hospitalized patients to be susceptible to amikacin and piperacillin-tazobactam; 80 to 90% of isolates to be susceptible to cefepime, ceftazidime, imipenem, and meropenem; and 70 to 80% of isolates to be susceptible to ciprofloxacin, gentamicin, levofloxacin, and ticarcillin-clavulanate. From 1998 to 2001, decreases in antimicrobial susceptibility (percents) among non-intensive-care-unit (non-ICU) inpatients and ICU patients, respectively, were greatest for ciprofloxacin (6.1 and 6.5), levofloxacin (6.6 and 3.5), and ceftazidime (4.8 and 3.3). Combined 1998 to 2001 results for A. baumannii isolated from non-ICU inpatients and ICU patients, respectively, demonstrated that >90% of isolates tested were susceptible to imipenem (96.5 and 96.6%) and meropenem (91.6 and 91.7%); fewer isolates from both non-ICU inpatients and ICU patients were susceptible to amikacin and ticarcillin-clavulanate (70 to 80% susceptible); and <60% of isolates were susceptible to ceftazidime, ciprofloxacin, gentamicin, or levofloxacin. From 1998 to 2001, rates of multidrug resistance (resistance to at least three of the drugs ceftazidime, ciprofloxacin, gentamicin, and imipenem) showed small increases among P. aeruginosa strains isolated from non-ICU inpatients (5.5 to 7.0%) and ICU patients (7.4 to 9.1%). From 1998 to 2001, rates of multidrug resistance among A. baumannii strains isolated from non-ICU inpatients (27.6 to 32.5%) and ICU patients (11.6 to 24.2%) were higher and more variable than those observed for P. aeruginosa. Isolates concurrently susceptible, intermediate, or resistant to both imipenem and meropenem accounted for 89.8 and 91.2% of P. aeruginosa and A. baumannii isolates, respectively, studied from 1998 to 2001. In conclusion, for aminoglycosides and most ß-lactams susceptibility rates for P. aeruginosa and A. baumannii were constant or decreased only marginally (<=3%) from 1998 to 2001. Greater decreases in susceptibility rates were, however, observed for fluoroquinolones and ceftazidime among P. aeruginosa isolates.

* Corresponding author. Mailing address: Focus Technologies, 13665 Dulles Technology Dr., Suite 200, Herndon, VA 20171-4603. Phone: (703) 480-2575. Fax: (703) 480-2654. E-mail: jkarlowsky{at}focusanswers.com.

Antimicrobial Agents and Chemotherapy, May 2003, p. 1681-1688, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1681-1688.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Morinaga, Y., Yanagihara, K., Nakamura, S., Yamamoto, K., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., Yamada, Y., Kohno, S., Kamihira, S. (2008). In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J Antimicrob Chemother 62: 1326-1331 [Abstract] [Full Text]  
  • Valentine, S. C., Contreras, D., Tan, S., Real, L. J., Chu, S., Xu, H. H. (2008). Phenotypic and Molecular Characterization of Acinetobacter baumannii Clinical Isolates from Nosocomial Outbreaks in Los Angeles County, California. J. Clin. Microbiol. 46: 2499-2507 [Abstract] [Full Text]  
  • Giske, C. G., Monnet, D. L., Cars, O., Carmeli, Y., on behalf of ReAct-Action on Antibiotic Resistance, (2008). Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli. Antimicrob. Agents Chemother. 52: 813-821 [Full Text]  
  • Kirikae, T., Mizuguchi, Y., Arakawa, Y. (2008). Investigation of isolation rates of Pseudomonas aeruginosa with and without multidrug resistance in medical facilities and clinical laboratories in Japan. J Antimicrob Chemother 61: 612-615 [Abstract] [Full Text]  
  • Reinert, R. R., Low, D. E., Rossi, F., Zhang, X., Wattal, C., Dowzicky, M. J. (2007). Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60: 1018-1029 [Abstract] [Full Text]  
  • Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., Bonomo, R. A. (2007). Global Challenge of Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 3471-3484 [Full Text]  
  • Kroeger, L. A., Hovde, L. B., Mitropoulos, I. F., Schafer, J., Rotschafer, J. C. (2007). Colistin Methanesulfonate against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 51: 3431-3433 [Abstract] [Full Text]  
  • Lodise, T. P., Miller, C. D., Graves, J., Furuno, J. P., McGregor, J. C., Lomaestro, B., Graffunder, E., McNutt, L.-A. (2007). Clinical Prediction Tool To Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multidrug Resistance. Antimicrob. Agents Chemother. 51: 417-422 [Abstract] [Full Text]  
  • Hawley, J. S., Murray, C. K., Griffith, M. E., McElmeel, M. L., Fulcher, L. C., Hospenthal, D. R., Jorgensen, J. H. (2007). Susceptibility of Acinetobacter Strains Isolated from Deployed U.S. Military Personnel. Antimicrob. Agents Chemother. 51: 376-378 [Abstract] [Full Text]  
  • Lolans, K., Rice, T. W., Munoz-Price, L. S., Quinn, J. P. (2006). Multicity Outbreak of Carbapenem-Resistant Acinetobacter baumannii Isolates Producing the Carbapenemase OXA-40.. Antimicrob. Agents Chemother. 50: 2941-2945 [Abstract] [Full Text]  
  • Bosso, J. A., Mauldin, P. D. (2006). Using Interrupted Time Series Analysis To Assess Associations of Fluoroquinolone Formulary Changes with Susceptibility of Gram-Negative Pathogens and Isolation Rates of Methicillin-Resistant Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2106-2112 [Abstract] [Full Text]  
  • Burgess, D. S., Frei, C. R. (2005). Comparison of {beta}-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 56: 893-898 [Abstract] [Full Text]  
  • Huys, G., Cnockaert, M., Nemec, A., Swings, J. (2005). Sequence-Based Typing of adeB as a Potential Tool To Identify Intraspecific Groups among Clinical Strains of Multidrug-Resistant Acinetobacter baumannii. J. Clin. Microbiol. 43: 5327-5331 [Abstract] [Full Text]  
  • Fish, D. N., Teitelbaum, I., Abraham, E. (2005). Pharmacokinetics and Pharmacodynamics of Imipenem during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob. Agents Chemother. 49: 2421-2428 [Abstract] [Full Text]  
  • Poole, K. (2005). Aminoglycoside Resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 479-487 [Full Text]  
  • Kuti, J. L., Nightingale, C. H., Nicolau, D. P. (2004). Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002. Antimicrob. Agents Chemother. 48: 2464-2470 [Abstract] [Full Text]  
  • Yamane, K., Doi, Y., Yokoyama, K., Yagi, T., Kurokawa, H., Shibata, N., Shibayama, K., Kato, H., Arakawa, Y. (2004). Genetic Environments of the rmtA Gene in Pseudomonas aeruginosa Clinical Isolates. Antimicrob. Agents Chemother. 48: 2069-2074 [Abstract] [Full Text]  
  • Corpus, K. A, Weber, K. B, Zimmerman, C. R (2004). Intrathecal Amikacin for the Treatment of Pseudomonal Meningitis. The Annals of Pharmacotherapy 38: 992-995 [Abstract] [Full Text]  
  • Yoon, J., Urban, C., Terzian, C., Mariano, N., Rahal, J. J. (2004). In Vitro Double and Triple Synergistic Activities of Polymyxin B, Imipenem, and Rifampin against Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48: 753-757 [Abstract] [Full Text]  
  • Segal, H., Nelson, E. C., Elisha, B. G. (2004). Genetic Environment and Transcription of ampC in an Acinetobacter baumannii Clinical Isolate. Antimicrob. Agents Chemother. 48: 612-614 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»